Socio-economic assessment of patient blood management practical implementation in surgical treatment of coronary heart disease (I20–I25)

Aim    To evaluate possible social and economic benefits of correcting preoperative iron deficiency /iron deficiency anemia as a comorbidity in a model population in the process of transition from the routine practice to the optimized preparation of patients to elective surgery (as exemplified by several circulatory diseases: I20 – I25, class IX ICD 10).
Material and methods    By building imitation models depending on the patient blood management (PBM) practice, changes in years of life lost/saved adjusted for disability were evaluated, including in monetary terms, in relation to the annual number of operations performed for ischemic heart disease (IHD) (I20 – I25) in the age group of 17 years and older, as well as a potential effect of PBM on the applied health economics.
Results    With implementation of the PBM systemic measures in cardiac surgery, the potentially prevented annual social and economic damage will amount to more than 38 thousand years of life saved and more than 20.2 billion rubles in monetary terms. Furthermore, it will be possible to exclude 9435 hemotransfusion from the cardiosurgical practice, which will annually save more than 2.3 thousand liters of blood with a total cost of 77.7 million rubles in favor of clinical situations that have no alternative.
Conclusion    The implementation of PBM in cardiac surgery, the discipline with the highest levels of preoperative iron deficiency/anemia and the use of blood components, will not only improve the clinical outcomes and cost-effectiveness of surgical interventions, but will also prevent social and economic damage to the country.

1. Fomin I.V. Chronic heart failure in Russian Federation: what do we know and what to do. Russian Journal of Cardiology. 2016;8:7–13. DOI: 10.15829/1560-4071-2016-8-7-13

2. Leonov S.A., Golubev N.A., Zaychenko N.M. Collection of statistical materials on diseases of the circulatory system. FRIHOI MH RF. Av. at: https://mednet.ru/images/stories/files/CMT/kardioilogiya_2017.pdf. 2017.

3. Aleksandrova G.A., Golubev N.A., Zalevskaya O.V., Shelepova E.A., Avdeeva L.N., Polikarpov A.V. Collection of statistical materials on diseases of the circulatory system. Moscow. 149p. Av. at: https://mednet.ru/images/materials/statistika/2021/22_kardiologiya_2019.doc.2020.

4. Muñoz M, Acheson AG, Auerbach M, Besser M, Habler O, Kehlet H et al. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia. 2017;72(2):233–47. DOI: 10.1111/anae.13773

5. Hofmann A, Farmer S, Towler SC. Strategies to preempt and reduce the use of blood products: an Australian perspective. Current Opinion in Anaesthesiology. 2012;25(1):66–73. DOI: 10.1097/ACO.0b013e32834eb726

6. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129–200. DOI: 10.1093/eurheartj/ehw128

7. Bhandari S. Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice. Therapeutics and Clinical Risk Management. 2011;7:501–9. DOI: 10.2147/TCRM.S25882

8. Kaserer A, Rössler J, Braun J, Farokhzad F, Pape H ‐C., Dutkowski P et al. Impact of a Patient Blood Management monitoring and feedback programme on allogeneic blood transfusions and related costs. Anaesthesia. 2019;74(12):1534– 41. DOI: 10.1111/anae.14816

9. Mehra T, Seifert B, Bravo-Reiter S, Wanner G, Dutkowski P, Holubec T et al. Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. Transfusion. 2015;55(12):2807–15. DOI: 10.1111/trf.13260

10. Meybohm P, Straub N, Füllenbach C, Judd L, Kleinerüschkamp A, Taeuber I et al. Health economics of Patient Blood Management: a cost‐benefit analysis based on a meta‐analysis. Vox Sanguinis. 2020;115(2):182–8. DOI: 10.1111/vox.12873

11. Kleinerüschkamp A, Meybohm P, Straub N, Zacharowski K, Choorapoikayil S. A model-based cost-effectiveness analysis of Patient Blood Management. Blood Transfusion. 2019;17(1):16–26. DOI: 10.2450/2018.0213-17

12. Geissler RG, Rotering H, Buddendick H, Franz D, Bunzemeier H, Roeder N et al. Utilisation of Blood Components in Cardiac Surgery: A Single-Centre Retrospective Analysis with Regard to Diagnosis-Related Procedures. Transfusion Medicine and Hemotherapy. 2015;42(2):75–82. DOI: 10.1159/000377691

13. Wells AW, Mounter PJ, Chapman CE, Stainsby D, Wallis JP. Where does blood go? Prospective observational study of red cell transfusion in north England. BMJ. 2002;325(7368):803. DOI: 10.1136/bmj.325.7368.803

14. Klein AA, Collier TJ, Brar MS, Evans C, Hallward G, Fletcher SN et al. The incidence and importance of anaemia in patients undergoing cardiac surgery in the UK - the first Association of Cardiothoracic Anaesthetists national audit. Anaesthesia. 2016;71(6):627–35. DOI: 10.1111/anae.13423

15. Murray CJL, Lopez AD. Measuring the Global Burden of Disease. New England Journal of Medicine. 2013;369(5):448–57. DOI: 10.1056/NEJMra1201534

16. Yagudina R.I., Kulikov A.Yu., Babiy V.V., Arinina E.E. Pharmacoeconomics of HIV-infection. Bulletin of Scientific Center for Expert Evaluation of Medicinal Products. 2015;4:58–63.

17. Prokhorov B.B., Shmakov D.I. The Costing of the Statistical Life and Economic Damage Due to Health Problems. Studies on Russian Economic Development. 2002;13(3):309–16. [Russian: Прохоров Б.Б., Шмаков Д.И. Оценка стоимости статистической жизни и экономического ущерба от потерь здоровья. Проблемы прогнозирования. 2002;3:125-35]

18. Revich B.A., Avaliani S.L., Bobylev S.N., Safonov G.V., Sidorenko V.N. Methodological guidelines. Economic assessment of public health losses as a result of exposure to adverse environmental factors. 2006; DOI: 10.13140/RG.2.2.17412.32646

19. Moscow City Compulsory Medical Insurance Fund. Tariff agreement for 2019. Av. at: https://www.mgfoms.ru/strahovye-kompanii/tarifi/2019. [Russian: Московский городской фонд обязательного медицинского страхования. Тарифное соглашение на 2019 год. Доступно на: https://www.mgfoms.ru/strahovye-kompanii/tarifi/2019]

20. World Health Organisation. Hemoglobin concentration for the diagnosis of anemia and assessment of its severity. Vitamin and Mineral Nutrition Information System. Av. at: https://www.who.int/vmnis/indicators/haemoglobin_ru.pdf.

21. Rössler J, Schoenrath F, Seifert B, Kaserer A, Spahn GH, Falk V et al. Iron deficiency is associated with higher mortality in patients undergoing cardiac surgery: a prospective study. British Journal of Anaesthesia. 2020;124(1):25–34. DOI: 10.1016/j.bja.2019.09.016

22. Sirbu O, Floria M, Dascalita P, Stoica A, Adascalitei P, Sorodoc V et al. Anemia in heart failure - from guidelines to controversies and challenges. The Anatolian Journal of Cardiology. 2018;20(1):52–9. DOI: 10.14744/AnatolJCardiol.2018.08634

23. Vatutin N.T., Sklyannaya E.V., Kirienko Т.S. Anemia in patients with chronic heart failure. Ukrainian Cardiology Journal. 2004;3:111–6.

24. Szachniewicz J, Petruk-Kowalczyk J, Majda J, Kaczmarek A, Reczuch K, Kalra PR et al. Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. International Journal of Cardiology. 2003;90(2–3):303–8. DOI: 10.1016/S0167-5273(02)00574-0

25. Stuklov N.I. Iron Deficiency and Anemia in Patients with Chronic Heart Failure. Rational Pharmacotherapy in Cardiology. 2017;13(5):651–60. DOI: 10.20996/1819-6446-2017-13-5-651-660

26. Charlot M, Torp-Pedersen C, Valeur N, Seibæk M, Weeke P, Køber L. Anaemia and Long Term Mortality in Heart Failure Patients: A Retrospective Study. The Open Cardiovascular Medicine Journal. 2010;4(1):173–7. DOI: 10.2174/1874192401004010173

27. Karkouti K, Wijeysundera DN, Beattie WS. Risk Associated with Preoperative Anemia in Cardiac Surgery: A Multicenter Cohort Study. Circulation. 2008;117(4):478–84. DOI: 10.1161/CIRCULATIONAHA.107.718353

28. von Heymann C, Kaufner L, Sander M, Spies C, Schmidt K, Gombotz H et al. Does the severity of preoperative anemia or blood transfusion have a stronger impact on long-term survival after cardiac surgery? The Journal of Thoracic and Cardiovascular Surgery. 2016;152(5):1412–20. DOI: 10.1016/j.jtcvs.2016.06.010

29. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ et al. Anemia and Mortality in Heart Failure Patients. Journal of the American College of Cardiology. 2008;52(10):818–27. DOI: 10.1016/j.jacc.2008.04.061

30. Murphy GJ, Reeves BC, Rogers CA, Rizvi SIA, Culliford L, Angelini GD. Increased Mortality, Postoperative Morbidity, and Cost After Red Blood Cell Transfusion in Patients Having Cardiac Surgery. Circulation. 2007;116(22):2544–52. DOI: 10.1161/CIRCULATIONAHA.107.698977

31. Shander A, Fink A, Javidroozi M, Erhard J, Farmer SL, Corwin H et al. Appropriateness of Allogeneic Red Blood Cell Transfusion: The International Consensus Conference on Transfusion Outcomes. Transfusion Medicine Reviews. 2011;25(3):232-246.e53. DOI: 10.1016/j.tmrv.2011.02.001

32. Mareev V.Yu., Gilyarevskiy S.R., Mareev Yu.V., Begrambekova Yu.L., Belenkov Yu.N., Vasyuk Yu.A. et al. Position Paper. The role of iron deficiency in patients with chronic heart failure and current corrective approaches. Kardiologiia. 2020;60(1):99–106. DOI: 10.18087/cardio.2020.1.n961

33. World Health Organisation. WHA63.12 - Availability, Safety and Quality of Blood Products. WHA resolution; Sixty-third World Health Assembly, 2010. [Internet] Available at: https://digicollections.net/medicinedocs/#d/s19998ru

34. World Health Organisation. Global Forum for Blood Safety: Patient Blood Management 14–15 March 2011, Dubai, United Arab Emirates. Av at: https://www.who.int/bloodsafety/events/gfbs_01_pbm_concept_paper.pdf.

35. Carson JL. Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB*. Annals of Internal Medicine. 2012;157(1):49–58. DOI: 10.7326/0003-4819-157-1-201206190-00429

36. Zhiburt E.B., Shestakov E.A. Evidence-based transfusiology. Part 1. On the rules for the appointment of blood components. Healthcare. 2007; 11:31–7.

37. Trekova N.A., Akselrod B.A., Guskov D.A., Solovyova I.N., Goloborodko V.G., Panin V.V. et al. Меthods of allogenic blood products decreasing in cardiac surgery. Clinical and Experimental Surgery. Petrovsky journal. 2015;1(7):57–65.